Valor20202021202220232024TTMGastos comerciales, generales y administrativos747 M818 M828 M926 M1.1 B—Investigación y desarrollo226 M230 M236 M274 M320 M—Beneficio operativo332 M389 M695 M813 M842 M—Total de ingresos no operativos——————Gastos por intereses, netos de intereses capitalizados——————Ingresos no operativos, una vez deducidos los gastos por intereses——————Ingresos/gastos extraordinarios——————Beneficio antes de impuestos361 M426 M734 M862 M900 M—Participación en los beneficios——————Impuestos125 M115 M186 M194 M229 M—Participación minoritaria————8 M—Otros ingresos/gastos después de impuestos——————Beneficio neto antes de actividades interrumpidas236 M311 M548 M668 M671 M—Operaciones suspendidas——————Beneficio neto236 M311 M548 M668 M671 M—Ajuste por dilución——————Dividendos de las acciones preferentes——————Beneficio neto diluido atribuible a los accionistas——————Beneficio básico por acción——————Beneficio por acción diluido——————Número medio de acciones ordinarias——————Acciones diluidas——————EBITDA——————EBIT1.52 B1.71 B1.99 B2.2 B2.42 B—Costo de los ingresos1.19 B1.32 B1.3 B1.39 B1.58 B—Otros costes de producción——————Amortización y depreciación (flujo de caja)——————
Dr. Reddy's Laboratories Ltd
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr.